Gujarat Magazine

DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including Oncolytic Virus Cancer Therapy clinical trials and non-clinical stage products. It also covers the Oncolytic Virus Cancer Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Oncolytic Virus Cancer Therapy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Oncolytic Virus Cancer Therapy clinical trials studies, Oncolytic Virus Cancer Therapy NDA approvals (if any), and product development activities comprising the technology, Oncolytic Virus Cancer Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report

 

• DelveInsight’s Oncolytic Virus Cancer Therapy Pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Virus Cancer Therapy treatment.

 

• The leading Oncolytic Virus Cancer Therapy Companies includes Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, GeneMedicine, GeneMedicine, GeneMedicine, Oncolys BioPharma, SillaJen Biotherapeutics, Turnstone Biologics, and others.

 

• Promising Oncolytic Virus Cancer Therapy Pipeline Therapies includes LOAd703, V937, OH2, CG0070, OBP-301, Vusolimogene oderparepvec, TG6002, Invir.IOTM based armed oncolytic immunotherapies, STI-1386, ORCA-010, TILT-123, CRX 100, Pelareorep, ONCR-177, ONCR-GBM, ONCR-021, ONCR-788, DNX-2401, DNX-2440, vMYX-hIL-12/Dec, Voyager-V1, MV-NIS, VCN 01, VCN 02, VCN 03, VCN 11, VSV-GP, CF33, RIVAL 01, MVR-T3011, Pexa-Vec, CAN-2409, CAN-3110, NOUS 209, NOUS PEV,  TVP 211, ELC-100, ELC-201, Valo D102, TT 16, NG 641, NG 350A, NG 348, NG 347, VET2 L2, VET3 NK, VET1 S3, ONCOS-102, MB-108, HF10, VAX014, NNV-1, NNV 2, SNV 1, AAA1, Olvi-Vec, BT-001, SND005, AdAPT-001, SVV-001, Celyvir, RV-scFv-PDL1, OV FV 01,  ASP9801, MEM 288, MEDI5395, PVSRIPO, G207, and others.

 

• The Oncolytic Virus Cancer Therapy companies and academics are working to assess challenges and seek opportunities that could influence Oncolytic Virus Cancer Therapy R&D. The Oncolytic Virus Cancer Therapy pipeline therapies under development are focused on novel approaches to treat/improve Oncolytic Virus Cancer Therapy.

 

To explore more information on the latest breakthroughs in the Oncolytic Virus Cancer Therapy Pipeline treatment landscape of the report, click here @ Oncolytic Virus Cancer Therapy Pipeline Outlook

 

Oncolytic Virus Cancer Therapy Overview

 

Oncolytic virotherapy is a treatment of using a virus that can replicate itself to kill cancer cells. There are many species of viruses, but not all of them can be designed to be an oncolytic virus (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity of being transformed to express tumor-killing factors through genetic engineering methods. Tumor selectivity could be concerned with the level of receptor-mediated cell entry, intracellular antiviral responses, or restriction factors that determine the susceptibility of the infected cell that leads to viral gene expression and replication.

 

Latest Developmental Activities in the Oncolytic Virus Cancer Therapy Treatment Landscape

 

• In February 2022, Synthetic Biologics announced that VCN Biosciences, VCN-01 received Orphan Drug Designation for retinoblastoma from the US Food & Drug Administration (FDA).

 

• In March 2022, Synthetic Biologics announced that it has completed the acquisition of VCN Biosciences, S.L. (VCN) following the satisfaction of all closing conditions.

 

• In September 2021, CG Oncology announced a clinical trial collaboration to evaluate the safety and efficacy of CG0070, an oncolytic immunotherapy, in combination with OPDIVO (nivolumab), Bristol Myers Squibb’s anti-PD-1 therapy, for the treatment of metastatic urothelial cancer in a Phase I/II clinical study.

 

• In March 2021, Orgenesis Inc. announced that it has entered the planned second phase of a collaboration with Hospital Infantil Universitario Niño Jesús in Madrid, Spain. The collaboration is focused on an exclusive license agreement to further develop and commercialize the hospital’s proprietary Celyvir therapy for the treatment of solid tumors.

 

For further information, refer to the detailed Oncolytic Virus Cancer Therapy Unmet Needs, Oncolytic Virus Cancer Therapy Market Drivers, and Oncolytic Virus Cancer Therapy Market Barriers, click here for Oncolytic Virus Cancer Therapy Ongoing Clinical Trial Analysis

 

Oncolytic Virus Cancer Therapy Emerging Drugs Profile

 

Olvi-Vec: Genelux Corporation

Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and anti-tumor activity. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits. Currently the product is in Phase III stage of development for the treatment of Platinum-Resistant/Refractory Ovarian Cancer

 

CAN-2409: Candel Therapeutics

CAN-2409 (aglatimagene besadenovec) is an adenovirus-based replication deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus. It is injected directly into the tumor or target tissue The prodrug-derived cytotoxic nucleotide analogs are designed to inhibit DNA replication and repair, leading to the death of multiplying tumor cells, and in particular of cells undergoing repair from radiation or chemotherapy damage. Currently the product is in Phase III stage of development for the treatment of Prostrate Cancer.

 

CG0070: CG Oncology

CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure. Currently the product is in Phase III stage of development for the treatment of Non Muscular Invasive Bladder Cancer.

 

Pelareorep: Oncolytics Biotech

Pelareorep, is an investigational drug being developed by Oncolytics Biotech. It is an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype — turning “cold” tumors “hot” — through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Currently the drug is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Metastatic Breast Cancer.

 

ParvOryx: Oryx GmbH

ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer and renal cancer, as well as tumor stem cells. H-1PV acts at relatively low multiplicities of infection. The virus exerts both cytotoxic and oncolytic (replication) effects. The cytotoxic effect is predominantly mediated by the non-structural protein (NS1), resulting in cell transcription dysregulation, cell cycle arrest, cell replication shut off, and activation of cellular stress response and induction of cell death. In addition, viral oncolysis induces a strong tumor-specific immune response leading to the recognition and elimination of minimal residual disease (bystander effect). ParvOryx is the smallest of all oncolytic viruses and is able to cross the blood brain barrier. Unlike other natural or modified oncolytic viruses currently under investigation, ParvOryx does not affect normal cells and is not pathogenic to humans. Currently the product is in Phase II stage of development for the treatment of pancreatic cancer.

 

SND005: Jiangsu Sinorda Biomedicine

SND005 Oncolytic virus is a type of virus that preferentially infects and kills tumor cells. Initially, some tumor cells were specifically infected and destroyed by oncolytic viruses. Subsequently, the oncolytic virus replicates and proliferates in tumor cells, releasing new infectious virus particles to infect and destroy other tumor cells. Oncolytic viruses exert their oncolytic effects by directly lysing tumor cells or stimulating the host to produce an anti-tumor immune response. Among the new oncolytic virus drugs currently underway, SND005 is the only wild-type virus without genetic modification. It has a 14 – year history of clinical use. In a trial of 540 patients with melanoma, more than 44% of the patients benefited. In the safety and tolerability study of 190 patients, no serious adverse events were found, and the most common adverse event was low-grade fever. The clinical data and observations after the overseas market show that the survival rate of patients is increased by 4- 5 times, and it has excellent performance in stage II melanoma patients.

 

VCN-01: VCN Biosciences

VCN-01 is an innovativeconditionally replicative oncolytic adenovirus expressing PH20 hyaluronidase. Expression of hyaluronidase from VCN-01 facilitates virus penetration and decreases intratumorfluid pressure, enhancing antibodyup-take. In addition, VCN-01 capsid has been modified to allow the virus to partially evade liver tropism and target selectively the tumor after intravenous administration. Currently the product is in Phase I stage of development for the treatment of Pancreatic, Serous Epithelial Ovarian Cancer and Squamous Cell of Head and Neck.

 

Oncolytic Virus Cancer Therapy Pipeline Therapeutics Assessment

 

There are approx. 120+ key companies which are developing the therapies for Oncolytic Virus Cancer Therapy. The companies which have their Oncolytic Virus Cancer Therapy drug candidates in the most advanced stage, i.e. phase III include, Genelux Corporation.

 

Request a sample and discover the recent advances in Oncolytic Virus Cancer Therapy Ongoing Clinical Trial Analysis and Medications, click here @ Oncolytic Virus Cancer Therapy Treatment Landscape

 

Scope of the Oncolytic Virus Cancer Therapy Pipeline Report

 

• Coverage- Global

 

• Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, GeneMedicine, GeneMedicine, GeneMedicine, Oncolys BioPharma, SillaJen Biotherapeutics, Turnstone Biologics, and others.

 

• Pipeline Therapies- LOAd703, V937, OH2, CG0070, OBP-301, Vusolimogene oderparepvec, TG6002, Invir.IOTM based armed oncolytic immunotherapies, STI-1386, ORCA-010, TILT-123, CRX 100, Pelareorep, ONCR-177, ONCR-GBM, ONCR-021, ONCR-788, DNX-2401, DNX-2440, vMYX-hIL-12/Dec, Voyager-V1, MV-NIS, VCN 01, VCN 02, VCN 03, VCN 11, VSV-GP, CF33, RIVAL 01, MVR-T3011, Pexa-Vec, CAN-2409, CAN-3110, NOUS 209, NOUS PEV,  TVP 211, ELC-100, ELC-201, Valo D102, TT 16, NG 641, NG 350A, NG 348, NG 347, VET2 L2, VET3 NK, VET1 S3, ONCOS-102, MB-108, HF10, VAX014, NNV-1, NNV 2, SNV 1, AAA1, Olvi-Vec, BT-001, SND005, AdAPT-001, SVV-001, Celyvir, RV-scFv-PDL1, OV FV 01,  ASP9801, MEM 288, MEDI5395, PVSRIPO, G207, and others.

 

• Oncolytic Virus Cancer Therapy Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

  

Dive deep into rich insights for drugs for Oncolytic Virus Cancer Therapy Market Drivers and Oncolytic Virus Cancer Therapy Market Barriers, click here @ Oncolytic Virus Cancer Therapy Unmet Needs and Analyst Views

 

Table of Content

 

1. Introduction
2. Executive Summary
3. Oncolytic Virus Cancer Therapy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Oncolytic Virus Cancer Therapy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Olvi-Vec: Genelux Corporation
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SND005: Jiangsu Sinorda Biomedicine
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. AloCelyvir: Orgenesis
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. VCN-01: VCN Biosciences
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. SynOV 1.3: Beijing Syngentech
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Oncolytic Virus Cancer Therapy Key Companies
24. Oncolytic Virus Cancer Therapy Key Products
25. Oncolytic Virus Cancer Therapy- Unmet Needs
26. Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
27. Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
28. Oncolytic Virus Cancer Therapy Analyst Views
29. Oncolytic Virus Cancer Therapy Key Companies
30. Appendix

 

Got Queries? Find out the related information on Oncolytic Virus Cancer Therapy Mergers and acquisitions, Oncolytic Virus Cancer Therapy Licensing Activities @ Oncolytic Virus Cancer Therapy Emerging Drugs, and Recent Trends

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/